Sedation	B:C0235195
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
sprays	O
versus	O
drops	O
on	O
pediatric	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

Sedation	O
effects	O
of	O
intranasal	B:C0442118
dexmedetomidine	O
delivered	O
as	O
sprays	O
versus	O
drops	O
on	O
pediatric	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

Sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	B:C0113293
delivered	O
as	O
sprays	O
versus	O
drops	O
on	O
pediatric	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

Sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
sprays	B:C0461725
versus	O
drops	O
on	O
pediatric	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

Sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
sprays	O
versus	O
drops	B:C0991568
on	O
pediatric	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

Sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
sprays	O
versus	O
drops	O
on	O
pediatric	O
response	O
to	O
venous	B:C0398266
cannulation	I:C0398266
.	O

Mucosal	B:C0025080
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	B:C0025080
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	B:C0442118
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	B:C2081612
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	B:C2603343
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	B:C0220825
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	B:C0235195
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	B:C0442118
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	B:C0113293
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	B:C0991568
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	B:C0461725
on	O
pediatric	O
responses	O
to	O
intravenous	O
cannulation	I:C0398266
.	O

Mucosal	O
atomization	I:C0025080
device	I:C0025080
(	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
)	O
was	O
designed	O
to	O
increase	O
the	O
bioavailability	O
of	O
intranasal	O
medications	O
by	O
facilitating	O
absorption	O
,	O
the	O
present	O
study	O
aimed	O
to	O
evaluate	O
and	O
compare	O
the	O
sedation	O
effects	O
of	O
intranasal	O
dexmedetomidine	O
delivered	O
as	O
drops	O
versus	O
sprays	O
on	O
pediatric	O
responses	O
to	O
intravenous	B:C0398266
cannulation	I:C0398266
.	O

One	O
hundred	O
and	O
six	O
pediatric	O
patients	O
(	O
aged	O
from	O
2	O
to	O
5	O
years	O
)	O
scheduled	O
for	O
elective	B:C0038901
ophthalmic	I:C0038901
surgery	I:C0038901
were	O
intranasally	O
received	O
a	O
dose	O
of	O
2μg/	O
kg	O
in	O
20μl	O
/	O
kg	O
of	O
dexmedetomidine	O
for	O
sedation	O
to	O
reduce	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

One	O
hundred	O
and	O
six	O
pediatric	O
patients	O
(	O
aged	O
from	O
2	O
to	O
5	O
years	O
)	O
scheduled	O
for	O
elective	O
ophthalmic	I:C0038901
surgery	I:C0038901
were	O
intranasally	B:C0442118
received	O
a	O
dose	O
of	O
2μg/	O
kg	O
in	O
20μl	O
/	O
kg	O
of	O
dexmedetomidine	O
for	O
sedation	O
to	O
reduce	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

One	O
hundred	O
and	O
six	O
pediatric	O
patients	O
(	O
aged	O
from	O
2	O
to	O
5	O
years	O
)	O
scheduled	O
for	O
elective	O
ophthalmic	I:C0038901
surgery	I:C0038901
were	O
intranasally	O
received	O
a	O
dose	O
of	O
2μg/	O
kg	O
in	O
20μl	O
/	O
kg	O
of	O
dexmedetomidine	B:C0113293
for	O
sedation	O
to	O
reduce	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

One	O
hundred	O
and	O
six	O
pediatric	O
patients	O
(	O
aged	O
from	O
2	O
to	O
5	O
years	O
)	O
scheduled	O
for	O
elective	O
ophthalmic	I:C0038901
surgery	I:C0038901
were	O
intranasally	O
received	O
a	O
dose	O
of	O
2μg/	O
kg	O
in	O
20μl	O
/	O
kg	O
of	O
dexmedetomidine	O
for	O
sedation	B:C0235195
to	O
reduce	O
response	O
to	O
venous	O
cannulation	I:C0398266
.	O

One	O
hundred	O
and	O
six	O
pediatric	O
patients	O
(	O
aged	O
from	O
2	O
to	O
5	O
years	O
)	O
scheduled	O
for	O
elective	O
ophthalmic	I:C0038901
surgery	I:C0038901
were	O
intranasally	O
received	O
a	O
dose	O
of	O
2μg/	O
kg	O
in	O
20μl	O
/	O
kg	O
of	O
dexmedetomidine	O
for	O
sedation	O
to	O
reduce	O
response	O
to	O
venous	B:C0398266
cannulation	I:C0398266
.	O

The	O
patients	O
were	O
randomized	B:C0034656
into	O
syringe	O
group	O
and	O
MAD	O
group	O
in	O
which	O
dexmedetomidine	O
was	O
delivered	O
as	O
drops	O
or	O
sprays	O
via	O
syringe	O
or	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
respectively	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
syringe	O
group	O
and	O
MAD	O
group	O
in	O
which	O
dexmedetomidine	B:C0113293
was	O
delivered	O
as	O
drops	O
or	O
sprays	O
via	O
syringe	O
or	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
respectively	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
syringe	O
group	O
and	O
MAD	O
group	O
in	O
which	O
dexmedetomidine	O
was	O
delivered	O
as	O
drops	B:C0991568
or	O
sprays	O
via	O
syringe	O
or	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
respectively	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
syringe	O
group	O
and	O
MAD	O
group	O
in	O
which	O
dexmedetomidine	O
was	O
delivered	O
as	O
drops	O
or	O
sprays	B:C0461725
via	O
syringe	O
or	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
respectively	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
syringe	O
group	O
and	O
MAD	O
group	O
in	O
which	O
dexmedetomidine	O
was	O
delivered	O
as	O
drops	O
or	O
sprays	O
via	O
syringe	B:C0039142
or	O
Mucosal	O
atomization	I:C0025080
device	I:C0025080
respectively	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
syringe	O
group	O
and	O
MAD	O
group	O
in	O
which	O
dexmedetomidine	O
was	O
delivered	O
as	O
drops	O
or	O
sprays	O
via	O
syringe	O
or	O
Mucosal	B:C0025080
atomization	I:C0025080
device	I:C0025080
respectively	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
response	O
to	O
peripheral	B:C1720192
vein	I:C1720192
cannulation	O
assessed	O
by	O
the	O
FLACC	O
scores	O
(	O
FLACC	O
scores	I:C0015450
,	O
legs	O
,	O
activity	O
,	O
cry	O
and	O
consolability	O
)	O
30	O
min	O
after	O
intranasal	O
administration	I:C0001560
of	O
dexmedetomidine	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
response	O
to	O
peripheral	O
vein	I:C1720192
cannulation	B:C0917707
assessed	O
by	O
the	O
FLACC	O
scores	O
(	O
FLACC	O
scores	I:C0015450
,	O
legs	O
,	O
activity	O
,	O
cry	O
and	O
consolability	O
)	O
30	O
min	O
after	O
intranasal	O
administration	I:C0001560
of	O
dexmedetomidine	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
response	O
to	O
peripheral	O
vein	I:C1720192
cannulation	O
assessed	O
by	O
the	O
FLACC	O
scores	O
(	O
FLACC	B:C0015450
scores	I:C0015450
,	O
legs	O
,	O
activity	O
,	O
cry	O
and	O
consolability	O
)	O
30	O
min	O
after	O
intranasal	O
administration	I:C0001560
of	O
dexmedetomidine	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
response	O
to	O
peripheral	O
vein	I:C1720192
cannulation	O
assessed	O
by	O
the	O
FLACC	O
scores	O
(	O
FLACC	O
scores	I:C0015450
,	O
legs	B:C1140621
,	O
activity	O
,	O
cry	O
and	O
consolability	O
)	O
30	O
min	O
after	O
intranasal	O
administration	I:C0001560
of	O
dexmedetomidine	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
response	O
to	O
peripheral	O
vein	I:C1720192
cannulation	O
assessed	O
by	O
the	O
FLACC	O
scores	O
(	O
FLACC	O
scores	I:C0015450
,	O
legs	O
,	O
activity	O
,	O
cry	O
and	O
consolability	O
)	O
30	O
min	O
after	O
intranasal	B:C0001560
administration	I:C0001560
of	O
dexmedetomidine	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
response	O
to	O
peripheral	O
vein	I:C1720192
cannulation	O
assessed	O
by	O
the	O
FLACC	O
scores	O
(	O
FLACC	O
scores	I:C0015450
,	O
legs	O
,	O
activity	O
,	O
cry	O
and	O
consolability	O
)	O
30	O
min	O
after	O
intranasal	O
administration	I:C0001560
of	O
dexmedetomidine	B:C0113293
.	O

The	O
secondary	O
outcomes	O
included	O
acceptance	O
for	O
intranasal	B:C0442118
medication	O
,	O
sedation	O
onset	O
time	O
,	O
and	O
needle	O
insertion	O
times	O
and	O
any	O
adverse	O
event	I:C0877248
at	O
the	O
preoperative	O
holding	I:C1301759
area	I:C1301759
.	O

The	O
secondary	O
outcomes	O
included	O
acceptance	O
for	O
intranasal	O
medication	B:C2081612
,	O
sedation	O
onset	O
time	O
,	O
and	O
needle	O
insertion	O
times	O
and	O
any	O
adverse	O
event	I:C0877248
at	O
the	O
preoperative	O
holding	I:C1301759
area	I:C1301759
.	O

The	O
secondary	O
outcomes	O
included	O
acceptance	O
for	O
intranasal	O
medication	O
,	O
sedation	B:C0235195
onset	O
time	O
,	O
and	O
needle	O
insertion	O
times	O
and	O
any	O
adverse	O
event	I:C0877248
at	O
the	O
preoperative	O
holding	I:C1301759
area	I:C1301759
.	O

The	O
secondary	O
outcomes	O
included	O
acceptance	O
for	O
intranasal	O
medication	O
,	O
sedation	O
onset	O
time	O
,	O
and	O
needle	B:C0027551
insertion	O
times	O
and	O
any	O
adverse	O
event	I:C0877248
at	O
the	O
preoperative	O
holding	I:C1301759
area	I:C1301759
.	O

The	O
secondary	O
outcomes	O
included	O
acceptance	O
for	O
intranasal	O
medication	O
,	O
sedation	O
onset	O
time	O
,	O
and	O
needle	O
insertion	O
times	O
and	O
any	O
adverse	B:C0877248
event	I:C0877248
at	O
the	O
preoperative	O
holding	I:C1301759
area	I:C1301759
.	O

The	O
secondary	O
outcomes	O
included	O
acceptance	O
for	O
intranasal	O
medication	O
,	O
sedation	O
onset	O
time	O
,	O
and	O
needle	O
insertion	O
times	O
and	O
any	O
adverse	O
event	I:C0877248
at	O
the	O
preoperative	B:C1301759
holding	I:C1301759
area	I:C1301759
.	O

The	O
FLACC	O
scores	O
in	O
MAD	O
group	O
were	O
significantly	O
decreased	O
than	O
that	O
treated	B:C0332293
by	O
drops	O
(	O
P=0.021	O
)	O
.	O

The	O
FLACC	O
scores	O
in	O
MAD	O
group	O
were	O
significantly	O
decreased	O
than	O
that	O
treated	O
by	O
drops	B:C0991568
(	O
P=0.021	O
)	O
.	O

The	O
acceptance	O
for	O
intranasal	B:C0001560
administration	I:C0001560
between	O
both	O
groups	O
was	O
comparable	O
(	O
P>0.05	O
)	O
,	O
the	O
onset	O
time	O
and	O
the	O
incidences	O
in	O
two	O
and	O
more	O
times	O
of	O
needle	O
insertion	O
did	O
not	O
differ	O
significantly	O
between	O
syringe	O
and	O
MAD	O
group	O
s	O
(	O
all	O
P>0.05	O
)	O
.	O

The	O
acceptance	O
for	O
intranasal	O
administration	I:C0001560
between	O
both	O
groups	O
was	O
comparable	O
(	O
P>0.05	O
)	O
,	O
the	O
onset	O
time	O
and	O
the	O
incidences	O
in	O
two	O
and	O
more	O
times	O
of	O
needle	B:C0027551
insertion	O
did	O
not	O
differ	O
significantly	O
between	O
syringe	O
and	O
MAD	O
group	O
s	O
(	O
all	O
P>0.05	O
)	O
.	O

None	O
of	O
patients	O
were	O
required	O
to	O
clinically	O
intervene	O
in	O
heart	B:C0018810
rates	I:C0018810
reduction	O
and	O
none	O
suffered	O
respiratory	O
depression	I:C0235063
after	O
administrations	O
of	O
dexmedetomidine	O
in	O
either	O
group	O
.	O

None	O
of	O
patients	O
were	O
required	O
to	O
clinically	O
intervene	O
in	O
heart	O
rates	I:C0018810
reduction	O
and	O
none	O
suffered	O
respiratory	B:C0235063
depression	I:C0235063
after	O
administrations	O
of	O
dexmedetomidine	O
in	O
either	O
group	O
.	O

None	O
of	O
patients	O
were	O
required	O
to	O
clinically	O
intervene	O
in	O
heart	O
rates	I:C0018810
reduction	O
and	O
none	O
suffered	O
respiratory	O
depression	I:C0235063
after	O
administrations	B:C3469597
of	O
dexmedetomidine	O
in	O
either	O
group	O
.	O

None	O
of	O
patients	O
were	O
required	O
to	O
clinically	O
intervene	O
in	O
heart	O
rates	I:C0018810
reduction	O
and	O
none	O
suffered	O
respiratory	O
depression	I:C0235063
after	O
administrations	O
of	O
dexmedetomidine	B:C0113293
in	O
either	O
group	O
.	O

Intranasal	B:C0442118
dexmedetomidine	O
by	O
sprays	O
offers	O
better	O
sedation	O
effects	O
to	O
reduce	O
responses	O
to	O
venous	O
cannulation	I:C0398266
than	O
drops	O
.	O

Intranasal	O
dexmedetomidine	B:C0113293
by	O
sprays	O
offers	O
better	O
sedation	O
effects	O
to	O
reduce	O
responses	O
to	O
venous	O
cannulation	I:C0398266
than	O
drops	O
.	O

Intranasal	O
dexmedetomidine	O
by	O
sprays	B:C0461725
offers	O
better	O
sedation	O
effects	O
to	O
reduce	O
responses	O
to	O
venous	O
cannulation	I:C0398266
than	O
drops	O
.	O

Intranasal	O
dexmedetomidine	O
by	O
sprays	O
offers	O
better	O
sedation	B:C0235195
effects	O
to	O
reduce	O
responses	O
to	O
venous	O
cannulation	I:C0398266
than	O
drops	O
.	O

Intranasal	O
dexmedetomidine	O
by	O
sprays	O
offers	O
better	O
sedation	O
effects	O
to	O
reduce	O
responses	O
to	O
venous	B:C0398266
cannulation	I:C0398266
than	O
drops	O
.	O

Intranasal	O
dexmedetomidine	O
by	O
sprays	O
offers	O
better	O
sedation	O
effects	O
to	O
reduce	O
responses	O
to	O
venous	O
cannulation	I:C0398266
than	O
drops	B:C0991568
.	O

